Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16739946 | 0.82 | NPC1 (0.31) | — | |
| SCHEMBL15663066 | 0.76 | FAAH (0.33) | — | |
| SCHEMBL3109165 | 0.75 | — | — | |
| SCHEMBL585201 | 0.70 | KDM4E (0.42) | KDM4E | |
| SCHEMBL3470585 | 0.70 | PTGDR2 (0.41) | KDM4E | |
| SCHEMBL1953951 | 0.70 | — | — | |
| SCHEMBL18282319 | 0.70 | SMN1; SMN2 (0.31) | — | |
| SCHEMBL11895145 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL29953864 | 0.69 | KDM4E (0.41) | KDM4E | |
| SCHEMBL9050 | 0.69 | DYRK1A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4650002-A1 | ANILINE-BASED MODULATORS OF THE NUCLEAR RECEPTOR TLX (NR2E1) | Ludwig-Maximilians-Universität (DE) | 2025-11-19 | — | — | EP | disclosed |
| EP-3351533-B1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-12227500-B2 | Substituted pyrrolo[2,3-b]pyridines for suppressing toxic endoplasmic reticulum stress | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-02-18 | — | — | US | disclosed |
| CN-117915903-A | Compounds for the treatment of neurodegenerative, degenerative and metabolic disorders and uses thereof | 佛罗里达大学研究基金会公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-18 | — | — | US | disclosed |
| US-20230399327-A1 | HIGH ACTIVITY HPK1 KINASE INHIBITOR | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| CN-116730978-A | Compound containing heteroaromatic ring alkynyl, preparation method and application thereof | 中国科学院上海药物研究所 | 2023-09-12 | — | — | CN | disclosed |
| CN-116685585-A | High-activity HPK1 kinase inhibitor | 杭州阿诺生物医药科技有限公司 | 2023-09-01 | — | — | CN | disclosed |
| WO-2023040818-A1 | COMPOUND THAT INHIBITS PROGRAMMED CELL NECROSIS, AND PREPARATION METHOD THEREFOR | 中国科学院上海有机化学研究所 | 2023-03-23 | — | — | WO | disclosed |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| EP-2114893-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009003719-A2 | INDANE-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-01-08 | — | — | WO | disclosed |
| EP-2011786-A1 | Indane-amine derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-07 | — | — | EP | disclosed |
| EP-1997807-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997493-A1 | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| EP-1975161-A1 | Heterocyclyl-substituted- tetrahydro-napthalen-amine derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-10-01 | — | — | EP | disclosed |
| WO-2008095689-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-08-14 | — | — | WO | disclosed |
| EP-1956006-A1 | Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2008-08-13 | — | — | EP | disclosed |
| EP-1935886-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399327-A1 | HIGH ACTIVITY HPK1 KINASE INHIBITOR | MAP3K9, MAP3K1, MAP3K15 | KDM4E 1899/4885 |
| US-12227500-B2 | Substituted pyrrolo[2,3-b]pyridines for suppressing toxic endoplasmic reticulum stress | HSPA5, ATP2A1, DNAJC10 | KDM4E 4033/4885 |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | HSPA5, ATP2A1, DNAJC10 | KDM4E 4033/4885 |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | MAP3K8, MAP3K1, MAP3K6 | KDM4E 3381/4885 |
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SNCA, NLN, HTT | KDM4E 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.